Champion Homes, Inc. (SKY)

Ligand Pharmaceuticals Stock Forecast

Stock Price Forecast

The 4 analysts that cover Ligand Pharmaceuticals stock have a consensus rating of "Buy" and an average price target of $86, which forecasts a 21.09% increase in the stock price over the next year. The lowest target is $74 and the highest is $99.

Price Target: $86 (+21.09%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$74	$86	$86	$99
Change	+4.20%	+21.09%	+21.09%	+39.40%

Analyst Ratings

The average analyst rating for Ligand Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Mar '25	Apr '25	May '25	Jun '25	Jul '25	Aug '25
Strong Buy	1	1	1	1	1	1
Buy	0	0	0	0	0	0
Hold	4	4	4	4	4	3
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	5	5	5	5	5	4

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Mike Dahl RBC Capital	RBC Capital	Hold Maintains $82 → $85	Hold	Maintains	$82 → $85	+19.68%	Aug 7, 2025
Matthew Bouley Barclays	Barclays	Hold Maintains $72 → $74	Hold	Maintains	$72 → $74	+4.20%	Aug 7, 2025
Mike Dahl RBC Capital	RBC Capital	Hold Maintains $96 → $82	Hold	Maintains	$96 → $82	+15.46%	May 28, 2025
Matthew Bouley Barclays	Barclays	Hold Maintains $97 → $72	Hold	Maintains	$97 → $72	+1.38%	May 28, 2025
Matthew Bouley Barclays	Barclays	Hold Maintains $106 → $97	Hold	Maintains	$106 → $97	+36.58%	Apr 8, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

2.63B

Increased by 5.98%

from 2.48B

Revenue Next Year

2.81B

Increased by 6.61%

from 2.63B

EPS This Year

3.29

Decreased by -3.70%

from 3.42

EPS Next Year

3.77

Increased by 14.62%

from 3.29

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Apr 3, 2021	Apr 2, 2022	Apr 1, 2023	Mar 30, 2024	Mar 29, 2025	Mar 31, 2026	Mar 31, 2027
Revenue	1.42B	2.21B	2.61B	2.02B	2.48B	2.63B	2.81B
Revenue Growth	3.73%	55.34%	18.09%	-22.32%	22.65%	5.98%	6.61%
EPS	1.49	4.33	7.00	2.53	3.42	3.29	3.77
EPS Growth	46.08%	190.60%	61.66%	-63.86%	35.18%	-3.70%	14.62%
Forward PE	-	-	-	-	-	21.56	18.81
No. Analysts	-	-	-	-	-	8	8

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027
High	2.9B	3.0B
Avg	2.6B	2.8B
Low	2.5B	2.6B

Revenue Growth

Revenue Growth	2026	2027
High	15.6%	15.7%
Avg	6.0%	6.6%
Low	-0.7%	-2.6%

EPS Forecast

EPS	2026	2027
High	3.47	4.20
Avg	3.29	3.77
Low	3.14	3.47

EPS Growth

EPS Growth	2026	2027
High	1.3%	27.5%
Avg	-3.7%	14.6%
Low	-8.3%	5.3%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.